CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code.

iECURE's ECUR-506 showed promising safety and efficacy in a Phase 1/2 study for neonatal-onset OTC deficiency, with no major safety issues. BMO Capital Markets upgraded Precision BioSciences to ...

I build robots that move, blink, and sometimes even creep you out. From animatronics to 3D printing experiments, I fuse mechanics, electronics, and creativity to bring ideas to life. Follow to see ...